CAROLINE SCHULENBERG: Open Payments
NPI 1770140824 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,725 in 33 payments from 14 companies in 2025. Trend: 2023 $1,075 · 2024 $879 · 2025 $1,725
Food & beverage: $1,725
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 7 | $516 |
| Ipsen Biopharmaceuticals, Inc | 2 | $252 |
| ABBVIE INC. | 8 | $197 |
| Mallinckrodt Hospital Products Inc. | 1 | $149 |
| Janssen Scientific Affairs, LLC | 1 | $139 |
| GENZYME CORPORATION | 1 | $125 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $101 |
| Janssen Biotech, Inc. | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Madrigal Pharmaceuticals | 1 | $28 |
Products named: TERLIVAZ, Bylvay, Livdelzi, IQIRVO, Vemlidy, DUPIXENT, XIFAXAN, LINZESS.
Industry payments across LA — which companies pay providers there.
